The purposes of the webinar are to provide clarification on the responsibilities of SANAS and SAHPRA with regards to Conformity Assessment Bodies (CABs) operating in South Africa and to have a discussion on the renewal process and expectations from the industry and SAHPRA. Date: Thursday, 14...
As part of its ongoing response to COVID-19 communications and following a series of successful public events, the South African Health Products Regulatory Authority (SAHPRA) will be hosting a Webinar on “Vaccine Safety and Adverse Events”. The propose of the Webinar is to provide a...
11 March 2022 Embargo: Immediate release The South Africa Health Products Regulatory Authority (SAHPRA) has noted that a safety report in relation to the COVID-19 Pfizer Comirnaty vaccine directed to the United States Food and Drug Administration (FDA) has been distributed on various communication platforms in South...
17 February 2022 Embargo: Immediate release Until recently, the treatment options for patients with mild-to-moderate COVID-19 have been limited. New oral antiviral medicines are becoming available for the treatment of confirmed COVID-19 in adults who do not require supplemental oxygen and who are at risk of...
adria Crehuet Cano via Unsplash...
7 February 2022 SAHPRA registered the Comirnaty vaccine from Pfizer Laboratories Pty (Ltd) on 25 January 2022, with conditions. SAHPRA also SAHPRA registered the Covid-19 Vaccine MC Pharma on 31 January 2022, with conditions. SAHPRA is currently also evaluating a number of applications for emergency use (Section...
14 January 2022 Embargo: Immediate release Joint Media Statement The South African Health Products Regulatory Authority (SAHPRA) has signed a Memorandum of Understanding (MOU) with the U.S. Pharmacopeia (USP) to help expand the availability of health products, including medical devices, that are safe, efficacious, and of assured quality. SAHPRA,...
23 December 2021 Embargo: Immediate release The South African Health Products Regulatory Authority (SAHPRA) initially registered the COVID-19 Vaccine Janssen, with conditions on 30 March 2021, in terms of section 15 of the Medicines and Related Substance Act (Act 101 of 1965). On 10 December 2021, SAHPRA received...
8 December 2021 Embargo: Immediate release The South African Health Products Authority (SAHPRA) initially approved the use of Pfizer’s Comirnaty® COVID-19 vaccine on 16 March 2021, in terms of section 21 of the Medicines and Related Substance Act (Act 101 of 1965). On 17 November 2021, SAHPRA received...
7 December 2021 Please note that the SAHPRA office will be closed for the festive season from 12h00 on Friday the 24th of December 2021 and will re-open on Monday the 3rd of January 2022. In case of emergencies kindly contact the respective Senior Managers. Medical Devices and...
